A new study published in The British Journal of Psychiatry showed that risperidone increases the risk of stroke in the individuals with dementia who have a history of cardiovascular ...

Risperidone is a second-generation antipsychotic that lacks acute motor side effects at low doses (<6 mg/day), but above this level is associated with parkinsonism and akathesia. The literature ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...

A final-stage clinical trial comparing a new long-acting, once-weekly pill to treat schizophrenia symptoms with the existing daily treatment has found that both produce comparable therapeutic effects.

Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and ...

In a randomized, double-blind study, we evaluated patients with schizophrenia and a poor response to treatment with clozapine. The patients continued to take clozapine and were randomly assigned to ...

UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults. 1 This approval marks a ...

Please provide your email address to receive an email when new articles are posted on . An oral, ultra-long-acting, extended-release risperidone capsule provided sustained therapeutic levels of ...

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, February 25, 2025--(BUSINESS WIRE)--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), ...

The antipsychotic cariprazine (Reagila) is not only more effective than risperidone in treating patients with schizophrenia and persistent negative symptoms (PNS), it is also safe and effective for ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...